Understanding GLP-1 Agonists: Complete Research Guide: A Microdosing Perspective
Microdose Take
Microdosing changes the calculus of medication choice. Tirzepatide's shorter half-life (5 days vs sema's 7) makes daily microdosing produce a flatter curve. Retatrutide's triple agonism (GLP-1 + GIP + glucagon) responds particularly well to split protocols. The comparison below covers the standard view; microdose-specific recommendations are noted.
⚠️ Educational only: GLP-1s are prescription medications. Microdose protocols are user-developed and not FDA-approved. Consult your prescribing healthcare provider before adjusting any dosing schedule.
Introduction to GLP-1 Agonists
GLP-1 (Glucagon-Like Peptide-1) agonists represent a revolutionary class of medications that have transformed the treatment landscape for metabolic health and weight management. These compounds work by mimicking the effects of the natural GLP-1 hormone, which plays a crucial role in glucose regulation and appetite control.
Receptor Targeting Comparison
Semaglutide
GLP-1
GIP
Glucagon
Single receptor activation
Tirzepatide
GLP-1
GIP
Glucagon
Dual receptor activation
Retatrutide
GLP-1
GIP
Glucagon
Triple receptor activation
CagriSema
GLP-1
Amylin
GIP
Dual mechanism (GLP-1 + Amylin)
Receptor Binding & Mechanisms
Microdose Tools & Resources
Microdose Calculator
Split-dose math
Microdose Schedule
Daily/EOD cadences
Plasma Plotter
Compare microdose vs weekly
Standard-Dose View
GLP1Calculator article
Disclaimer: GLP1Microdose.com is independent and not affiliated with Novo Nordisk, Eli Lilly, or any pharmaceutical manufacturer. Microdosing protocols are not FDA-approved dosing regimens. This article is educational only and does not constitute medical advice.